Alaunos Therapeutics Inc TCRT
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-08-20 |
| Shares Out. | 2,440,000 |
| Website | alaunos.com/ ↗ |
| Phone | 13463554099 |
| Employees | 1 |
| Net Income | -$1.0M |
| Free Cash Flow | -$3.2M |
| Total Assets | $1.9M |
| Total Liabilities | $595,000 |
| Equity | $1.3M |
About Alaunos Therapeutics Inc
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Alaunos Therapeutics Inc is a publicly traded company under the ticker symbol TCRT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2025-03-01)